As tariffs drop dramatically (US from 145% to 30%, China from 125% to 10%), these companies could see immediate benefits from reduced costs and increased business activity across borders.
Markets have already started responding positively to the tariff cuts. Getting in now could position you to benefit if the 90-day window leads to a more permanent trade agreement.
While many investors are still figuring out what these tariff cuts mean, you can get ahead by focusing on these carefully selected companies already positioned to benefit from US-China trade improvements.
This collection focuses on companies that stand to benefit from reduced trade tensions between the US and China. With tariffs dropping dramatically (US from 145% to 30%, China from 125% to 10%), these stocks could see improved business conditions and investor confidence.
This 90-day tariff reduction represents a temporary easing of trade tensions that could reduce market uncertainty. While the long-term outlook depends on whether a more conclusive deal is reached by August 2025, these selected companies may benefit from this trading window.
We've handpicked big-name US and Chinese stocks that rely heavily on cross-border business or have significant market presence in both countries. These companies are potentially positioned to capitalize on increased trade activity and improved business sentiment.
These carefully selected stocks could see growth as the US and China significantly lower trade tariffs. Our analysts have identified companies positioned to benefit from increased trade between the world's two largest economies.
Market capitalisation breakdown for the basket and investor key takeaways summarised.
TSLA: $1.47T
AAPL: $3.90T
BABA: $397.68B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+1
Here are a few of the assets in this group. Create an account to unlock the full list.
Unlock all stocks by downloading the app for FREE.
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+25.15%
On average, analysts expect assets in this group to grow 25.15% over the next year.
9 of 11 assets in this group are rated Buy by professional analysts.
